PROPETAMPHOS (SAFROTIN)
Carcinogen And Pesticide Branch 1. General Discussion
This evaluation was undertaken to determine the effectiveness of a GFF as a sampling media for propetamphos. 1.1.2. Toxic effects (This section is for information only and should not be taken as the basis of OSHA policy). The following paragraph is excerpted from the book OCCUPATIONAL DISEASES, A Guide To Their Recognition. Ref. 5.1.) The organic phosphorus compounds act as irreversible inhibitors of cholinesterase, thereby allowing the accumulation of large amounts of acetylcholine. When a critical level of cholinesterase depletion is reached, usually about 20% of normal, symptoms and signs of acetylcholine accumulation poisoning become manifest. Symptoms may include blurred vision, weakness, nausea, headache, abdominal cramps, chest discomfort and diarrhea. Signs may include miosis, muscle twitching, salivation, sweating, tearing, cyanosis, convulsions and coma. (Ref. 5.1.) Besides being absorbed following inhalation or ingestion, organophosphorus pesticides are readily absorbed through the intact skin (Ref. 5.1.). When a particular pesticide has a low dermal LD50, a skin notation should be added to the TLV or PEL. Propetamphos has an acute oral LD50 of 119 mg/kg for male rats and an acute dermal LD50 of 2300 mg/kg for male rats. (Ref. 5.2.) By comparison with other organophosphorus insecticide 0.2 mg/m3, without a skin notation, was used in this evaluation. 1.1.3. Potential workplace exposure No estimate of worker exposure to propetamphos could be found. Propetamphos is used as an insecticide. (Ref.5.2) 1.1.4. Physical properties (Ref. 5-2.-5.4.)
1.2. Limit defining parameters The detection limit of the analytical procedure is 0.013 ng per injection This is the amount of analyte which will give a peak whose height is approximately five times the baseline noise. This detection limit takes into account a split ratio of 32 to 1 used in the capillary GC. 2. Sampling Procedure
2.1.2. A Glass Fiber Filter, 37-mm diameter, Gelman type A or equivalent. 2.1.3. A Cassette filter holder for 37-mm filter, Millipore M000037A0 or equivalent.(see figure 1.) 2.2. Reagents No sampling reagents are required. 2.3. Sampling technique
2.3.2. Attach the cassette to the sampling pump with flexible tubing. 2.3.3. Attach the cassette vertically in the employee's breathing zone in such a manner that it does not impede work performance. 2.3.4. After sampling for the appropriate time, remove the cassette and seal with plastic plugs. 2.3.5. Wrap each cassette end-to-end with an OSHA seal (Form 21). 2.3.6. Record the air volume for each sample, and list any possible interferences. 2.3.7. Submit at least one blank for each set of sample. Handle the blank in the same manner as the sample, except no air is drawn through it. 2.3.8. Submit bulk samples for analysis in a separate container. Do not ship with Air sample. 2.4. Extraction efficiency Three GFFs were each liquid spiked with 10 µL of a 1.41 mg/mL solution of propetamphos in toluene. They were then extracted with 3.0 mL of toluene and analyzed as in Section 3. The average recovery was 95.2%.
Extraction Study
2.5. Retention efficiency Six GFFs were each liquid spiked with 10 µL of a 1.41 mg/mL solution of propetamphos in toluene. After overnight storage in a drawer at room tempreture, 60 liters of humid air were drawn through each GFF. Three of these GFFs, along with a blank GFF, werc then extracted and analyzed as in Section 3. The average recovery was 90.3%. The remaining three spiked GFFs were used in the storage study.
Retention Efficiency Study
2.6. Sample storage The remaining three spiked GFFs from Section 2.5. (and a blank GFF) were stored for 8 days in a drawer at room temperature. They were then extracted and analyzed as in Section 3. The average recovery was 90.4%.
Storage Study
2.7. Recommended air volume and sampling rate
2.7.2. The recommended flow rate is 1.0 L/min. 2.8. Interferences (sampling) It is not known if any compounds will interfere with the collection of propetamphos. Suspected interferences should be reported to the laboratory with submitted samples. 2.9. Safety precautions (sampling)
2.9.2. Follow all safety practices that apply to the work area being sampled. 3. Analytical Procedure
3.1.2. A GC column capable of resolving propetamphos from any interferences. A 60 m x 0.32 mm i.d. SE-30 GC capillary column, 0.25 µm thick film, was used in this evaluation and is available from Supelco, Inc., Bellefonte, PA. 3.1.3. An electronic integrator or other suitable means of measuring detector response. A Hewlett-Packard 3392A Integrator and a Hewlett-Packard 3357 data system were used in this evaluation. 3.1.4. Vials, 4-mL and 2-mL glass with PTFE-lined septa. 3.1.5. Volumetric flasks, pipets, and syringes. 3.2. Reagents
3.2.2. Toluene, Pesticide grade. 3.2.3. Propetamphos. A 38.6% (w/w) solution in 1,3,5 trimethyl-benzene from the EPA was used in this evaluation. 3.3. Standard preparation Prepare stock standards by adding toluene to preweighed amounts of propetamphos. Prepare working range standards by diluting stock solutions with toluene. Store stock and dilute standards in a freezer. 3.4. Sample preparation
3.4.2. Add 3.0 ml. of toluene to each vial. 3.4.3. Seal the vials with Polytetrafluroethlene (PTFE) lined septa. Allow them to extract for one hour periodically shaking by hand . 3.4.4. If necessary, transfer aliquots of the samples to the vials used in GC analysis. In this evaluation the samples were transferred to 2-mL glass vials, sealed with PTFE lined septa, and loaded on the automatic sampler. 3.5. Analysis
3.5.2. Chromatogram (See Figure 2.) 3.6. Interferences (analytical)
3.6.2. Retention time on a single column is not proof of chemical identity. Analysis by an alternate GC column, flame photometric detector (FPD) and confirmation by mass spectrometry are additional means of identification. 3.7. Calculations
3.7.2. Determine the concentration of propetamphos in samples and blank from the calibration curve. If propetamphos is found in the blank make a blank correction. 3.7.3. Determine the air concentration by the following formula.
3.8. Safety precautions (analytical)
3.8.2. Avoid exposure to all solvents. 3.8.3. Wear safety glasses at all times. 4. Recommendations for Further Study
4.2. A fully validated method should be developed.
![]()
![]()
5. References
5.2. "Farm Chemicals Handbook"; Meister Publishing Co.; Willoughby, OH, 1985; p C195. 5.3. Windholz, M., Ed.; "Merck Index", 10th ed.; Merck and Co.; Rahway, NJ, 1983; p 1126. 5.4. Registry of Toxic Effects of Chemical Substances, 1978 Edition. (Lewis, R.J. and Tatken, R.L., Eds.) U.S. Department of Health, Education and Welfare, Public Health Services, Center for Disease Control, National Institute for Occupational Safety and Health, U.S. Government Printing Office, Washington, D.C.(1978). |